Industry · Biotech

AI for biotech decisions founders face

AI for biotech decisions at the founder level: platform vs asset, partnering vs going it alone, fundraising cadence, regulatory strategy, scientific leadership hires. Never medical, clinical, or scientific advice.

Start free See how it works

In short

No. SynthBoard is built for founder business decisions — fundraising, partnering, hiring, regulatory strategy, IPO timing. It does not provide scientific, clinical, medical or regulatory advice and is not a substitute for licensed professionals.

Last reviewed October 1, 2026

An example

One ask, start to finish.
What comes back is a memo.

How a board takes a call like this: her read, who sits, what they ask first, then the call — with how sure they are, who disagreed and the first step.

Biotech

Example · Board of 3

Should we license our platform to big pharma now or push to Phase 1 ourselves?

Chief of staff

This one needs a board: The Strategist, The Regulator and The CFO. The Strategist maps competitive dynamics and strategic options across multi-year horizons. Each researches alone first, then they react to one another — and on a decision, two of them take opposed sides.

The StrategistCompetitive Expert
The RegulatorCompliance Expert
The CFOFinancial Controller

Asked first

Has a competitor already made this move?

Yes, one hasNot that I knowWe’d be first

The board’s call

Push for the strategic partnership now rather than the crossover round.

Pre-Phase 1 partnerships preserve optionality on asset 2 and 3. Crossover dilution is structural — every round you take, the exit math gets harder.

Confidence70 · Moderate

The CFO disagreed

“Partnership terms can quietly cap your exit — read the change-of-control clauses”

First step Test what The CFO flagged before you commit.this week

Board of 3 · up to 135 credits on the card · an example, not a recorded run

Other asks people bring here

Several asks in one message become several rooms, each with its expert and its own price on the card. Keep or drop any, then convene them together.

When do we raise our crossover round vs push for a strategic deal first? — The Regulator, up to 85 credits
Should we hire a CMO before or after our IND filing? — The CFO, up to 85 credits
How do we structure a co-development deal that doesn't cap our future exit? — The Scientist, up to 85 credits

What you get

What she handles.
On this kind of call.

Frames the platform vs asset decision

Focus on a single asset, or sell the platform? The Strategist and The Investor argue the dilution math against the optionality.

Pressure-tests partnering vs go-it-alone

Pharma partnership, co-development deal, or full ownership through Phase 2? The CFO and The Strategist surface the trade-offs your BD team will rationalize away.

Stress-tests fundraising cadence

When to raise, how much, from whom, at what dilution. The Investor and The CFO argue with each other so you do not over-raise or under-raise.

Frames scientific & executive hiring

When do you hire a CSO, a CMO, a head of regulatory? The Empath and The Strategist work through the org-design call most biotech founders defer too long.

Why SynthBoard

Why SynthBoard for this.
Not one voice. A board.

Strategic framing only — never scientific or medical advice

SynthBoard is for founder business decisions about biotech companies. It does not give scientific, clinical, medical, regulatory or investment advice and is not a substitute for licensed professionals. Its experts are AI and can be wrong.

Built for capital-intensive, long-cycle businesses

Biotech runs on 7–12 year horizons. The experts reason in those timeframes — not the quarterly cadence built for SaaS.

Investor & regulator perspective on one board

The Investor thinks like a board and a downstream acquirer. The Regulator frames the FDA strategic posture. Together: the trade-offs founders normally pay a room of advisors to assemble.

Who sits

The experts for this call.
Each one holds a position.

Your Chief of Staff proposes who sits for the call, and every board is built with someone whose job is to argue against the obvious answer. Name an expert and they take a seat; tell her who you want on your board and they sit by default. How many seats a board has depends on your plan.

Competitive Expert

The Strategist

Don’t ask whether it’s good. Ask what your competitor does the day after you ship it.

The Strategist Competitive Expert

Best on: Positioning, entering a market, pricing against a rival.
Won’t let you: Plan a move as if nobody will answer it.

Try asking The Strategist

Start with

The StrategistOpen on every plan, Free included

Pick an expert

Hover, tap or tab throughSwipe, then tap one

GPT
Claude
Gemini
Grok

Seats are spread across model families: GPT, Claude, Gemini, Grok and more.

In their words

Biotech founders spend years on the science and minutes on the deal structure that decides whether they keep the company. A board is where you correct that imbalance — before the term sheet, not after.

The Investor VC PartnerOn biotech strategic decisions

Questions

Fair questions.
Straight answers.

What people ask before they bring this call to a board.

Does SynthBoard give scientific, clinical, or medical advice?

Will The Regulator or The Scientist replace my regulatory consultants?

No. These experts help you frame the strategic shape of a decision — when to file, what to prioritize, what to ask your specialists. The submission, the scientific design and the primary-source work stay with your consultants and counsel.

Is this useful for therapeutics, diagnostics, or biotech platforms specifically?

All three — who sits shifts with the motion. Therapeutics founders lean on The Regulator and The Investor; diagnostics on The CFO and The Strategist (reimbursement-driven); platforms on The Strategist and The Investor (partnership economics).

How does it handle the platform vs asset decision specifically?

It argues both sides. On a decision, at least two experts are assigned opposed positions: The Strategist argues for platform optionality, The Investor tests what the market actually pays for. The memo keeps the dissent instead of one optimistic recommendation.

Can it help model the impact of a partnership term sheet?

It helps you frame what to negotiate for — change of control, milestone triggers, opt-out gates. The term sheet review and the negotiation stay with your BD counsel and dealmakers.

Is my IP-sensitive content protected?

Your rooms are private to your account and encrypted at rest, and a memo is shared only when you share it. For the most sensitive IP — specific structures, unpublished data — frame the decision in higher-level terms.

SynthBoard (synthboard.ai) is one place for your business, your life, and every hard call. Your Chief of Staff keeps what you tell her on file, and 24 named experts on different AI models take the calls — one expert for a consult, a board with opposed seats for the hard ones — and hand back a memo with the call, the dissent and the first move. How it works.